Based on favorable results from KEYNOTE-859, the maker of pembrolizumab announced that it has cleared Health Canada for certain gastric cancers -- a high burden disease worldwide:
. . .First approved in Canada in 2015, Keytruda holds indications across various disease areas including advanced renal cell carcinoma, bladder cancer, and non-small cell lung carcinoma, among others.
Merck Canada Oncology Business Unit executive director and vice-president André Galarneau said: “We are proud of the recent expansion of Keytruda’s indications in gastric cancers, which often go undetected until an advanced stage, at which point patients face a poor prognosis.
“This milestone underscores our commitment to helping improve the lives of patients by offering treatment options that can lead to better health outcomes. . . .”
Now you know -- be excellent to one another. . . on a beautiful Spring morning here!
नमस्ते
No comments:
Post a Comment